PH12016502415A1 - Treatment of severe hypertriglyceridemia - Google Patents

Treatment of severe hypertriglyceridemia

Info

Publication number
PH12016502415A1
PH12016502415A1 PH12016502415A PH12016502415A PH12016502415A1 PH 12016502415 A1 PH12016502415 A1 PH 12016502415A1 PH 12016502415 A PH12016502415 A PH 12016502415A PH 12016502415 A PH12016502415 A PH 12016502415A PH 12016502415 A1 PH12016502415 A1 PH 12016502415A1
Authority
PH
Philippines
Prior art keywords
treatment
severe hypertriglyceridemia
mbx
type
hypertriglyceridemia
Prior art date
Application number
PH12016502415A
Other languages
English (en)
Inventor
Boudes Pol
Choi Yun-Jung
Robert L Martin
Charles A Mcwherter
Original Assignee
Cymabay Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cymabay Therapeutics Inc filed Critical Cymabay Therapeutics Inc
Publication of PH12016502415A1 publication Critical patent/PH12016502415A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PH12016502415A 2014-06-26 2016-12-02 Treatment of severe hypertriglyceridemia PH12016502415A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462017444P 2014-06-26 2014-06-26
PCT/US2015/037596 WO2015200580A1 (en) 2014-06-26 2015-06-25 Treatment of severe hypertriglyceridemia

Publications (1)

Publication Number Publication Date
PH12016502415A1 true PH12016502415A1 (en) 2017-02-27

Family

ID=53511030

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12016502415A PH12016502415A1 (en) 2014-06-26 2016-12-02 Treatment of severe hypertriglyceridemia

Country Status (16)

Country Link
US (1) US20150374649A1 (enExample)
EP (1) EP3160458A1 (enExample)
JP (1) JP2017519028A (enExample)
KR (1) KR20170020514A (enExample)
CN (1) CN106470675A (enExample)
AU (1) AU2015279905A1 (enExample)
BR (1) BR112016028918A2 (enExample)
CA (1) CA2951280A1 (enExample)
CL (1) CL2016003290A1 (enExample)
EA (1) EA201790091A1 (enExample)
HK (1) HK1231380A1 (enExample)
IL (1) IL249757A0 (enExample)
MX (1) MX2016017081A (enExample)
PH (1) PH12016502415A1 (enExample)
SG (1) SG11201610243YA (enExample)
WO (1) WO2015200580A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
ES2701094T3 (es) 2014-03-20 2019-02-20 Cymabay Therapeutics Inc Tratamiento de enfermedades colestáticas intrahepáticas
CA2944139C (en) 2014-04-11 2020-11-03 Cymabay Therapeutics, Inc. Treatment of nafld and nash
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
CA3085951C (en) * 2017-12-21 2022-10-11 Kowa Company, Ltd. Methods of treatment of hypertriglyceridemia
US20210145774A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Treatment of alcoholic liver disease
WO2021097034A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Seladelpar for use in the treatment of intestinal barrier dysfunction and associated diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA87467C2 (xx) 2003-09-19 2009-07-27 Янссен Фармацевтика Н.В 4-((феноксіалкіл)тіо)феноксіоцтова кислота та її аналоги$4-((феноксиалкил)тио)феноксиуксусная кислота и ее аналоги
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
SG183529A1 (en) * 2010-03-30 2012-10-30 Novartis Ag Uses of dgat1 inhibitors

Also Published As

Publication number Publication date
MX2016017081A (es) 2017-05-01
CL2016003290A1 (es) 2017-09-08
EP3160458A1 (en) 2017-05-03
SG11201610243YA (en) 2017-01-27
IL249757A0 (en) 2017-02-28
EA201790091A1 (ru) 2017-07-31
CN106470675A (zh) 2017-03-01
WO2015200580A1 (en) 2015-12-30
BR112016028918A2 (pt) 2017-08-22
AU2015279905A1 (en) 2017-02-02
JP2017519028A (ja) 2017-07-13
KR20170020514A (ko) 2017-02-22
CA2951280A1 (en) 2015-12-30
US20150374649A1 (en) 2015-12-31
HK1231380A1 (zh) 2017-12-22

Similar Documents

Publication Publication Date Title
IL278150A (en) A transgenic bacterium for the treatment of diseases related to hyperammonemia
PH12016501978B1 (en) Treatment of nafld and nash
EP3145875A4 (en) Electrochemical treatment methods
EP3154590A4 (en) Combination therapy with glutaminase inhibitors
EP3116872A4 (en) Combination therapy with glutaminase inhibitors
EP3047729A4 (en) Circulating fish culture method and circulating fish culture device
EP3197552A4 (en) Skin treatment appliance with changeable workpiece
HK1231380A1 (zh) 严重高甘油三酯血症的治疗
AU362827S (en) Rack system
EP3169748A4 (en) Salt tolerant friction reducer
DK3229840T3 (da) 3,5-dihydroxy-4-isopropyl-trans-stilben til anvendelse i topisk behandling af akne
AU363946S (en) Catheter gripper aid
IL249560A0 (en) Pyridinones converted with phenyl and tertbutyl acetic acid have anti-AIDS effects
LT3229790T (lt) Kompozicijos, apimančios vidutinės grandinės trigliceridus, skirtos panaudoti epilepsijos gydyme
EP3209143A4 (en) Feeding algae to cattle at low doses to produce high omega 3 levels in beef
PH12016502311A1 (en) Omega-3 analogues
HUE052786T2 (hu) Diszlipidémia elleni aktivitással rendelkezõ étrendi kompozíció
EP3183270A4 (en) Hiv antibody therapy as treatment substitute
EP3197470A4 (en) Cis-gnetin h and trans-gnetin h as therapeutic agents
EP3194030A4 (en) Substituted phenylpyrrolecarboxamides with therapeutic activity in hiv
AU363026S (en) Body for juice extractor
UA91814U (uk) Спосіб лікування вторинної метаболічної кардіоміопатії в дітей з дифузним нетоксичним зобом
AU357019S (en) A bracket
PT3862003T (pt) Inibidor de sglt-2 para utilização no tratamento de um distúrbio metabólico em animais felinos
AU358941S (en) Cornice guide